Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
In an unprecedented situation Biogen sought to restrict the use of Aduhelm weeks after the drug’s approval. And the FDA said yes.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.